Photodynamic prevention for GvHD (graft-versus-host disease) shows promise :
This article was originally published in Clinica
Theratechnologies subsidiary Celmed BioSciences says that it is gearing up to start human trials of its Theralux photodynamic process for preventing and treating graft-versus-host disease (GvHD) later this year. The announcement follows positive results from a new study - the first to be conducted in vitro on immunoreactive T cells, notes the Montreal, Canada firm. The study showed that the cells responsible for GvHD were selectively eliminated by the Theralux process, without destroying dormant T cells carrying immune and anti-leukaemic functions. The findings appear in Blood (July 15).